

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14875-170US1	Application No. 10/594,605
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Haruo Sugiyama et al.	
		Filing Date September 28, 2006	Group Art Unit 1637

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	A1	2007/0287175	12/13/2007	Sugiyama et al.			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	A2	WO 96/38176	12/05/1996	WIPO			English Abstract	
	A3	WO 99/03506	01/28/1999	WIPO			English Abstract	
	A4	WO 2005/092394	06/10/2005	WIPO			English Abstract	
	A5	WO 2005/092393	06/10/2005	WIPO			English Abstract	

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	A6	Borkhardt et al., "Blocking oncogenes in malignant cells by RNA interference – new hope for a highly specific cancer treatment?", 2(3):167-168, 2002.
	A7	Davies et al., "Development of an siRNA-based method for repressing specific genes in renal organ culture and its use to show that the WT1 tumor suppressor is required for nephron differentiation", Human Molecular Genetics 13(2):235-246, 2004.
	A8	Elmaagacli et al., "WT1 and BCR-ABL specific small interfering RNA have additive effects in the induction of apoptosis in leukemic cells", Haematologica 90(3):326-334, 2005.
	A9	Hosen et al., "Very low frequencies of human normal CD34 ⁺ hematopoietic progenitor cells express the Wilms' tumour gene WT1 at levels similar to those in leukaemia cells", Br. J. Haematol. 116(2):409-420, 2002.
	A10	Inoue et al., "Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells", Blood 91(8):2969-2976, 1998.
	A11	Kanato et al., "The Wilms' tumor gene WT1 is a common marker of progenitor cells in fetal liver", Biochem. Biophys. Res. Commun. 326:836-843, 2005.
	A12	Menssen et al., "Wilms' tumor gene (WT1) expression as a panleukemic marker", Int. J. Hematol. 76(2):103-109, 2002.
	A13	Menssen et al., "Wilms' tumor gene expression in human CD34 ⁺ hematopoietic progenitors during fetal development and early clonogenic growth", Blood 89(9):3486-3487, 1997.
	A14	Morrison et al., "A proteomic investigation of the role of WT-1 in disease", Biochemical Society Transactions 32(4):116A, 2004.
	A15	Mourellatos et al., "miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs", Genes Dev. 16(6):720-728, 2002.
	A16	Murata et al., "The Wilms' tumor suppressor gene WT1 induces G1 arrest and apoptosis in myeloblastic leukemia M1 cells", FEBS Letters 409(1):41-45, 1997.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14875-170US1	Application No. 10/594,605
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Haruo Sugiyama et al.	
		Filing Date September 28, 2006	Group Art Unit 1637

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	A17	Oji et al., "Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth", Japanese Journal of Cancer Research 90:194-204, 1999.
	A18	Yamagami et al., "Growth inhibition of human leukaemic cells by WT1 (Wilms' tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis", Blood 87(7):2878-2884, 1996.

Examiner Signature /Michail Belyavskyi/	Date Considered 1/11/10
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.B./